

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9969)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 31 AUGUST 2023

References are made to the notice of extraordinary general meeting (the “**EGM Notice**”) and the circular (the “**EGM Circular**”) of InnoCare Pharma Limited (the “**Company**”) dated 16 August 2023. Unless otherwise indicated, capitalized terms used herein have the same meanings of those defined in the EGM Circular.

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that the EGM was held on Thursday, 31 August 2023 and all proposed resolutions set out in the EGM Notice were duly passed by the Shareholders by way of poll.

The poll results in respect of the resolutions are as follows:

Ordinary Resolutions		No. of Votes Cast (%)		
		For	Against	Abstain
1.	To consider and approve the adoption of the 2023 Share Award Scheme and authorize the Directors to implement the 2023 Share Award Scheme.	757,134,905 92.0916%	65,018,886 7.9084%	4,350
2.	Conditional on the passing of the ordinary resolution no. 1, to consider and approve the Service Provider Sublimit and authorize the Directors to implement the Service Provider Sublimit.	757,133,905 92.0916%	65,018,886 7.9084%	5,350

Shareholders may refer to the EGM Notice and EGM Circular for the full text of the above resolutions.

As more than 1/2 of the votes present at the EGM in person or by proxy were cast in favour of each of the resolutions numbered 1 to 2 above, these resolutions were duly passed as ordinary resolutions of the Company.

Apart from the above resolutions, no new proposal was submitted for voting and approval.

GENERAL

As at the date of the EGM, the total number of issued Shares was 1,764,321,452 Shares (including 1,499,673,235 Hong Kong Shares and 264,648,217 RMB Shares), which was the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the EGM.

To the best of the knowledge, information and belief of the Board, there were no Shares entitling the Shareholders to attend and abstain from voting in favour of any of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required to abstain from voting at the EGM under the Listing Rules. No Shareholder had indicated in the EGM Circular that they intended to vote against or to abstain from voting on any resolutions proposed at the EGM.

All Directors have attended the EGM in person or by electronic means.

The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking in respect of the resolutions.

By Order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and executive Director

Hong Kong, 31 August 2023

As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.